01 August 2005
M2000: A Revolution in Pharmacology
Abbas Mirshafiey, Salvatore Cuzzocrea, Bernd Rehm, Hidenori MatsuoMed Sci Monit 2005; 11(8): PI53-63 :: ID: 202335
Abstract
Background: The tolerability and the anti-inflammatory and immunosuppressiveproperties of a novel designed non-steroidal anti-inflammatory drug, M2000 (beta-D-mannuronic acid),were investigated in various experimental models. Material/Methods: The anti-inflammatory and immunosuppressiveproperties of M2000 were tested in experimental models of rheumatoid arthritis (AIA) and multiple sclerosis(EAE). Its therapeutic potency on kidney diseases was studied using experimental models of nephrosisand immune complex glomerulonephritis (ICG). Biocompatibility and pharmacotoxicology assessment of M2000was carried out using a fibrosarcoma cell line, zymography, and serum and urine determinants. Results:Data showed that oral and/or i.p. administration of M2000 significantly reduces paw edema and histopathologicalparameters in arthritic rats. The immunosuppressive property of M2000 could significantly diminish clinicalsigns and histological erosions in the EAE model. Lymph node cell proliferation assay in EAE confirmedthe immunosuppressive efficacy of the tested drug. Our findings in ICG and experimental nephrosis showedthat M2000 enables a significant decrease in proteinuria, BUN, serum creatinine and cholesterol, as wellas glomerular lesion in M2000-treated rats. Moreover, this drug inhibited MMP-2 activity. The pharmacotoxicologystudy showed that M2000 is the safest anti-inflammatory and immunosuppressive drug in comparison withdexamethasone and conventional NSAIDs tested. Additionally, M2000 had no ulcerogenic effect on the ratstomach. Conclusions: M2000 is the first novel designed NSAID with the lowest molecular weight, no gastro-nephrotoxicity,and therapeutic effects in glomerulonephritis and nephrosis and could be strongly recommended on an extensivescale as the safest drug for decreasing anti-inflammatory reactions.
Keywords: Hydrocarbons - administration & dosage, Hydrocarbons - therapeutic use, Multiple Sclerosis - chemically induced, Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Antibodies - immunology, Arthritis, Experimental - pathology, Arthritis, Rheumatoid - pathology, Cattle, Cell Proliferation - drug effects, Glomerulonephritis - urine, Hindlimb - pathology, Hydrocarbons - therapeutic use, Immunosuppression, Interleukin-6 - metabolism, Lipids - blood, Matrix Metalloproteinase 2 - metabolism, Multiple Sclerosis - pathology, Neurons - pathology, Rats, Inbred Lew, Serum Albumin, Bovine - immunology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952